摘要
目的探讨血清糖类抗原对非小细胞肺癌诊断及转归的临床意义。方法采用多种肿瘤标志物蛋白芯片检测系统,化学发光法测定并分析164例确诊为非小细胞肺癌患者血清CA125、CA19-9、CA153、CA242水平。结果非小细胞肺癌血清CA19-9、CA125、CA153阳性检出率较健康对照组、肺良性疾病组显著升高(P<0.05);随着分期由早到晚,4种糖类抗原阳性检出率呈逐渐升高的趋势,其中CA125、CA153的早期和总的阳性检出率升高较CA19-9、CA242更加明显(P<0.05);CA19-9、CA242、CA125、CA153可随着病情的控制下降,恶化则增高。结论非小细胞肺癌患者4种糖类抗原的检测对诊断、监测疾病进展、判断预后有一定价值。
Objective To explore the diagnostic and prognostic value of the serum levels of four tumor carbohydrate antigens in non-small cell lung cancer patients. Methods Serum levels of CA19-9,CA242,CA125 and CA153 were measured with multiple tumor marker protein biochip detective system in 164 patients with non-small cell lung cancer,47 patients with various benign pulmonary diseases and 235 controls. Results The positive rates of CA19-9,CA125 and CA153 in the patients with non-small cell lung cancer were significantly higher than those in the controls and the patients with benign pulmonary diseases （P〈0.05）. The positive rates of four tumor carbohydrate antigens of the patients in late stage were higer than those of the patients in early stage. The positive rates of CA125 and CA153 were significantly higher than those of CA19-9 and CA242. The serum levels of CA19-9,CA242, CA125 and CA153 in patients with non-small cell lung could decrease while the tumor was cured and it could increase while tumor advanced. Conclusion Determination of the serum levels of CA19-9,CA242,CA125 and CA153 have definite value for the diagnosis and outcome prediction in the patients with non small cell lung cancer.
出处
《重庆医学》
CAS
CSCD
北大核心
2009年第5期552-553,555,共3页
Chongqing medicine
关键词
非小细胞肺癌
糖类抗原
蛋白芯片
non-small cell lung cancer
carbohydrate antigen
protein biochip detective system
